HLA-DR antigen-negative acute myeloid leukemia

Wetzler, M; McElwain, B K; Stewart, C C; Blumenson, L; Mortazavi, A; Ford, L A; Slack, J L; Barcos, M; Ferrone, S; Baer, M R
April 2003
Leukemia (08876924);Apr2003, Vol. 17 Issue 4, p707
Academic Journal
Human leukocyte antigen (HLA) Class II antigens are variably expressed on acute myeloid leukemia (AML) blasts. The biological and clinical significance of HLA Class II antigen expression by AML cells is not known. Therefore, we sought to characterize cases of AML without detectable HLA-DR expression. Samples from 248 consecutive adult AML patients were immunophenotyped by multiparameter flow cytometry at diagnosis. HLA-DR antigens were not detected on AML cells from 43 patients, including 20 with acute promyelocytic leukemia (APL), and 23 with other subtypes of AML. All APL cases had t(15;17), but there were no characteristic chromosome abnormalities in non-APL cases. No direct expression of other antigens was identified in HLA-DR-negative APL and nonAPL cases. Interestingly, cells from three HLA-DR-negative non-APL patients had similar morphology to that of the hypogranular variant of APL. This morphology, however, was not present in any HLA-DR-positive AML cases. Treatment response was similar in the 23 HLA-DR-negative non-APL and the 205 HLA-DR-positive patients. Finally, relapse was infrequently associated with changes in HLA-DR antigen expression, as the HLA-DR antigen was lost at relapse in only 4% of HLA-DR-positive cases, and was gained at relapse in only 17% of HLA-DR-negative cases. We conclude that HLA-DR-negative AML includes approximately equal numbers of APL and nonAPL cases, and that the morphology of HLA-DR-negative nonAPL cases can mimic the hypogranular variant of APL. The diagnosis of APL cannot be based on morphology and lack of HLA-DR antigen expression; rather, it requires cytogenetic or molecular confirmation.


Related Articles

  • Re-evaluation of various molecular targets located on CD34+CD38-Lin- leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia. YUPING CHENG; MING JIA; YUANYUAN CHEN; HAIZHAO ZHAO; ZEBIN LUO; YONGMIN TANG // Oncology Letters;Jan2016, Vol. 11 Issue 1, p891 

    Leukemia stem cells (LSCs) are hypothesized to be capable of driving the development of leukemia, and are responsible for disease relapse. Antibody therapy targeting cell surface antigens has significantly improved the treatment outcomes of leukemia. Therefore, it is important to identify cell...

  • Reciprocal bone marrow transplantation between brother and sister. Rana, I.; Pinto, R.M.; Caniglia, M.; Lombardi, A.; De Rossi, G. // Bone Marrow Transplantation;4/15/2002, Vol. 29 Issue 8, p705 

    Presents a case report on a child with acute myeloid leukemia who underwent allogeneic bone marrow transplantation from a human lymphocyte antigen-identical sister donor. Insight on familial leukemia and lymphoma; Information on the patient's condition; Recommendations for treatment.

  • New combination therapy shows effectiveness in elderly patients with AML.  // Hem/Onc Today;12/10/2010, Vol. 11 Issue 23, p31 

    The article focuses on a study which indicates that the complete remission rates of standard therapy in elderly patients with acute myeloid leukemia doubled with human leukocyte antigen (HLA)-mismatched granulocyte colony-stimulating factor-mobilized donor peripheral blood stem cells with...

  • Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis. Michel, G; Boulad, F; Small, T N; Black, P; Heller, G; Castro-Malaspina, H; Childs, B H; Gillio, A P; Papadopoulos, E B; Young, J W; Kernan, N A; O’Reilly, R J // Bone Marrow Transplantation;7/15/97, Vol. 20 Issue 2, p107 

    Leukemia cutis (LC) is a rare feature of acute myeloblastic leukemia (AML). Little information is available regarding its prognostic influence on post-transplant outcome. In our institution, 202 patients with AML received an allogeneic HLA-identical marrow transplant from related donors between...

  • Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Berlin, C; Kowalewski, D J; Schuster, H; Mirza, N; Walz, S; Handel, M; Schmid-Horch, B; Salih, H R; Kanz, L; Rammensee, H-G; Stevanović, S; Stickel, J S // Leukemia (08876924);Mar2015, Vol. 29 Issue 3, p647 

    Identification of physiologically relevant peptide vaccine targets calls for the direct analysis of the entirety of naturally presented human leukocyte antigen (HLA) ligands, termed the HLA ligandome. In this study, we implemented this direct approach using immunoprecipitation and mass...

  • Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells. Lanza, F; Castagnari, B; Rigolin, G; Moretti, S; Latorraca, A; Ferrari, L; Bardi, A; Castoldi, G // Leukemia (08876924);Oct97, Vol. 11 Issue 10, p1700 

    A quantitative analysis of expression levels of GM-CSF receptors was performed by flow cytometry in different disease categories, ie AML (n = 72), ALL (n = 18), and MDS (n = 12), as well as 12 healthy volunteers, using three different unconjugated GM-CSF/R monoclonal antibodies (McAbs) (HGM-CSFR...

  • Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: In reply. Zander, R. Axel; Bacher, Ulrike; Finke, Jürgen // Deutsches Aerzteblatt International;2/6/2009, Vol. 106 Issue 6, p1 

    The authors argue on the study on the transplantation of allogeneic stem cell in acute myeloid leukemia (AML). They say that such study did not prove the relevance of transplantation of HLA identical unrelated donors to sibling donor transplantation. The comparison of dose reduced conditioning...

  • BMT improved OS, DFS in intermediate-risk AML.  // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p45 

    The article discusses research which investigated how disease risk affects the efficacy of bone marrow transplantation (BMT) in children with intermediate-risk acute myeloid leukemia. It references the Children's Oncology Group study published in the "Journal of Clinical Oncology." The study has...

  • NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML. Schlegel, Patrick; Ditthard, Kerstin; Lang, Peter; Mezger, Markus; Michaelis, Sebastian; Handgretinger, Rupert; Pfeiffer, Matthias // Journal of Immunology Research;7/8/2015, Vol. 2015, p1 

    Natural killer cells have been shown to be relevant in the recognition and lysis of acute myeloid leukemia. In childhood acute lymphoblastic leukemia, it was shown that HLA I expression and KIR receptor-ligand mismatch significantly impact ALL cytolysis. We characterized 14 different primary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics